Bactrim Dosage for Wound Infection
For an adult with a wound infection and normal renal function, the recommended dosage of Bactrim (trimethoprim-sulfamethoxazole) is 1-2 double-strength tablets (160/800 mg) twice daily for 7-10 days.
Dosing Recommendations Based on Infection Type
For Skin and Soft Tissue Infections (SSTI)
The IDSA guidelines for skin and soft tissue infections provide clear dosing for wound infections 1:
- Standard adult dose: 1-2 double-strength tablets (160/800 mg TMP-SMX) twice daily orally
- Pediatric dose: 8-12 mg/kg/day based on trimethoprim component, divided into 2 doses
- Duration: Typically 7 days, depending on clinical response
This dosing applies specifically to wound infections where MRSA coverage is needed, as Bactrim has bactericidal activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus 2.
Clinical Context and Evidence
The 2014 IDSA guidelines note that while Bactrim's efficacy for SSTI is "poorly documented" in their tables, recent high-quality research has validated its effectiveness 1. A 2016 randomized trial demonstrated that TMP-SMX at 320/1600 mg twice daily for 7 days achieved a 92.9% cure rate for uncomplicated wound infections in settings where MRSA was prevalent 3. Another 2016 trial showed TMP-SMX produced similar cure rates to clindamycin (91.9% vs 92.1%) for uncomplicated wound infections 4.
Important Caveats
Bactrim has limitations for wound infections:
Poor anaerobic coverage: The guidelines explicitly state Bactrim has "good activity against aerobes; poor activity against anaerobes" 2. For bite wounds or infections likely involving anaerobes, combination therapy with metronidazole or alternative agents like amoxicillin-clavulanate is preferred 5.
Streptococcal resistance: Some strains of Streptococcus pyogenes may be resistant 1.
Not first-line for all wound types: For animal or human bite wounds, amoxicillin-clavulanate is preferred as monotherapy because it covers both aerobes and anaerobes 5.
Dosing Adjustments
For renal impairment (per FDA label) 6:
- CrCl >30 mL/min: Standard dosing
- CrCl 15-30 mL/min: Reduce dose by 50%
- CrCl <15 mL/min: Not recommended
Recent pharmacokinetic data suggests a 16.7% dose reduction for eGFR of 30 mL/min/1.73m² and 33.3% reduction for eGFR of 10 mL/min/1.73m² 7.
Practical Considerations
The 1-2 tablet range allows for severity-based dosing:
- 1 double-strength tablet twice daily may suffice for mild, uncomplicated wound infections
- 2 double-strength tablets twice daily (equivalent to 320/1600 mg) is appropriate for more significant infections and was the dose used in the landmark abscess trial 3
Monitor for adverse effects, which occur in approximately 12-25% of patients, primarily gastrointestinal symptoms (usually mild) 3, 4. The drug is contraindicated in sulfonamide allergy and should be avoided in pregnancy near term due to kernicterus risk 8.
Consider culture-guided therapy when possible, as emerging TMP-SMX resistance in S. aureus has been documented 9, and combination with rifampin may be beneficial for resistant strains 10.